Metastatic cancer

Common Name(s)

Metastatic cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Metastatic cancer" returned 3335 free, full-text research articles on human participants. First 3 results:

Efficacy of cetuximab in metastatic colon cancer - case report.
 

Author(s): V T Grigorean, A N Ciuhu, G Rahnea Nita, V Strambu, D N Straja, M Popescu, A M Sandu, R A Rahnea Nita

Journal: Chirurgia (Bucur). ;109(3):383-9.

 

In recent years, targeted therapies have proved effective in the treatment of colon cancer, but even in these conditions,metastatic disease is generally considered incurable.Cetuximab is approved for the treatment of advanced colorectal cancer patients with KRAS wild-type, in order ...

Last Updated: 24 Jun 2014

Go To URL
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.
 

Author(s): Vijayalakshmi Shanmugam, Ramesh K Ramanathan, Nicole A Lavender, Shripad Sinari, Manpreet Chadha, Winnie S Liang, Ahmet Kurdoglu, Tyler Izatt, Alexis Christoforides, Hollie Benson, Lori Phillips, Angela Baker, Christopher Murray, Galen Hostetter, Daniel D Von Hoff, David W Craig, John D Carpten

Journal:

 

The outcome of patients with metastatic colorectal carcinoma (mCRC) following first line therapy is poor, with median survival of less than one year. The purpose of this study was to identify candidate therapeutically targetable somatic events in mCRC patient samples by whole genome ...

Last Updated: 1 Jul 2014

Go To URL
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
 

Author(s): Momar Diouf, Benoist Chibaudel, Thomas Filleron, Christophe Tournigand, Marine Hug de Larauze, Marie-Line Garcia-Larnicol, Sarah Dumont, Christophe Louvet, Nathalie Perez-Staub, Alexandra Hadengue, Aimery de Gramont, Franck Bonnetain

Journal:

 

Health-related quality of life (QoL) has prognostic value in many cancers. A recent study found that the performance of prognostic systems for metastatic colorectal cancer (mCRC) were improvable. We evaluated the independent prognostic value of QoL for overall survival (OS) and its ...

Last Updated: 4 Jun 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Metastatic cancer" returned 350 free, full-text review articles on human participants. First 3 results:

Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer.
 

Author(s): Amy S Clark, Elizabeth McDonald, M Camilla Lynch, David Mankoff

Journal: Oncology (Williston Park, N.Y.). 2014 May;28(5):424-30.

 

As we enter the era of personalized medicine, tests that can inform on molecular mechanisms of cancer, and on breast cancer in particular, are in high demand. We currently use DNA- or RNA-based tests of gene expression and/or immunohistochemistry to better characterize a given breast ...

Last Updated: 9 Jul 2014

Go To URL
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
 

Author(s): John M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, Axel Heidenreich, Cora N Sternberg, Bertrand Tombal, Antonio Alcaraz, Amit Bahl, Sergio Bracarda, Giuseppe Di Lorenzo, Eleni Efstathiou, Stephen P Finn, Sophie Fosså, Silke Gillessen, Pirkko-Liisa Kellokumpu-Lehtinen, Frédéric E Lecouvet, Stephane Oudard, Theo M de Reijke, Craig N Robson, Maria De Santis, Bostjan Seruga, Ronald de Wit

Journal: Eur. J. Cancer. 2014 Jun;50(9):1617-27.

 

The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel ...

Last Updated: 20 May 2014

Go To URL
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
 

Author(s): Tobias Engel Ayer Botrel, Otávio Clark, Rodolfo Borges dos Reis, Antônio Carlos Lima Pompeo, Ubirajara Ferreira, Marcus Vinicius Sadi, Francisco Flávio Horta Bretas

Journal:

 

Prostate cancer is the most common cancer in older men in the United States (USA) and Western Europe. Androgen deprivation (AD) constitutes, in most cases, the first-line of treatment for these cases. The negative impact of CAD in quality of life, secondary to the adverse events of ...

Last Updated: 5 Feb 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
 

Status: Recruiting

Condition Summary: Metastatic Cancer; Metastatic Melanoma; Renal Cancer; Colorectal Cancer; Ovarian Cancer; Lung Cancer

 

Last Updated: 24 Jul 2014

Go to URL

Last Updated: 26 Sep 2014

Go to URL
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
 

Status: Recruiting

Condition Summary: Advanced Cancer; Metastatic Cancer; Solid Tumors

 

Last Updated: 9 Sep 2013

Go to URL